This is a highly material insider buying cluster — two directors and two 10% owners collectively invested over $300M at $16/share, signaling strong conviction. Traders should view this as a bullish signal, especially given the size (over 10% of market cap) and participation of strategic investors. Monitor for follow-up filings or corporate news that may have prompted this coordinated buying.
Price Chart
Executive Summary
Multiple 10% owners and directors of Kailera Therapeutics (KLRA) collectively purchased $318.75 million in stock over a 7-day window, including open-market buys totaling that amount. The transactions signal strong confidence from top insiders, particularly Bain Capital and key directors, amid no concurrent negative corporate developments.
Key Financial Metrics
Key Facts
- BAIN CAPITAL INVESTORS LLC purchased $134.38M in shares via open-market transactions on 2026-04-20.
- Director Kaplan Andrew T. bought $134.38M in shares on the open market on the same day.
- Director Koppel Adam and Bain Capital Life Sciences Investors, LLC each bought $25.00M in shares.
- All open-market purchases occurred at $16/share; total cluster value is $318.75M.
- Numerous derivative conversions and grants occurred but were non-cash events with $0 value.
Financial Impact
$318.75 million in net insider buying over 7 days
Risk Factors
- Large open-market purchases could exert upward pressure on share price in the short term, increasing volatility.
- Future disclosures may reveal these purchases were part of pre-arranged plans or subject to reversal if market conditions shift.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KLRA-1776852303089 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 3 | $14.91 $12.92 | ▼ −13.35% | ▼ −12.85% | $10.39 (−30.32%) |
Aug 12, 2026 7w ago | 8-K | $17.97 $17.47 | ▼ −2.78% | ▼ −0.82% | $10.39 (−42.18%) |
Jul 31, 2026 9w ago | Court Ruling | $16.94 $18.66 | ▲ +10.15% | ▲ +6.64% | $10.39 (−38.67%) |
Jul 24, 2026 10w ago | Court Ruling | $17.69 $17.05 | ▼ −3.62% | ▼ −3.99% | $10.39 (−41.27%) |
Jun 5, 2026 17w ago | Press Release | $19.70 $19.67 | ▼ −0.15% | ▼ −2.26% | $10.39 (−47.26%) |
May 26, 2026 18w ago | 8-K | $21.91 $22.38 | ▲ +2.15% | ▲ +1.68% | $10.39 (−52.58%) |
May 26, 2026 18w ago | Press Release | $21.91 $22.59 | ▲ +3.10% | ▲ +1.90% | $10.39 (−52.58%) |
May 13, 2026 20w ago | Press Release | $21.11 $19.62 | ▼ −7.06% | ▼ −5.90% | $10.39 (−50.78%) |
Apr 20, 2026 23w ago | 8-K | $25.22 $23.82 | ▼ −5.55% | ▼ −6.63% | $10.39 (−58.80%) |
Apr 20, 2026 23w ago | Insider Cluster | $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $10.39 (−57.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access